» Articles » PMID: 38619661

Dual Function of Activated PPARγ by Ligands on Tumor Growth and Immunotherapy

Overview
Journal Med Oncol
Publisher Springer
Specialty Oncology
Date 2024 Apr 15
PMID 38619661
Authors
Affiliations
Soon will be listed here.
Abstract

As one of the peroxisome-proliferator-activated receptors (PPARs) members, PPARγ is a ligand binding and activated nuclear hormone receptor, which is an important regulator in metabolism, proliferation, tumor progression, and immune response. Increased evidence suggests that activation of PPARγ in response to ligands inhibits multiple types of cancer proliferation, metastasis, and tumor growth and induces cell apoptosis including breast cancer, colon cancer, lung cancer, and bladder cancer. Conversely, some reports suggest that activation of PPARγ is associated with tumor growth. In addition to regulating tumor progression, PPARγ could promote or inhibit tumor immunotherapy by affecting macrophage differentiation or T cell activity. These controversial findings may be derived from cancer cell types, conditions, and ligands, since some ligands are independent of PPARγ activity. Therefore, this review discussed the dual role of PPARγ on tumor progression and immunotherapy.

Citing Articles

Molecular Iodine Improves the Efficacy and Reduces the Side Effects of Metronomic Cyclophosphamide Treatment against Mammary Cancer Progression.

Delgado-Gonzalez E, Rios-Arellano E, Anguiano B, Aceves C Int J Mol Sci. 2024; 25(16).

PMID: 39201507 PMC: 11354407. DOI: 10.3390/ijms25168822.

References
1.
Palmer C, Hsu M, Griffin H, Johnson E . Novel sequence determinants in peroxisome proliferator signaling. J Biol Chem. 1995; 270(27):16114-21. DOI: 10.1074/jbc.270.27.16114. View

2.
Zhang Z, Xu Y, Xu Q, Hou Y . PPARγ against tumors by different signaling pathways. Onkologie. 2013; 36(10):598-601. DOI: 10.1159/000355328. View

3.
Gou Q, Che S, Chen M, Chen H, Shi J, Hou Y . PPARγ inhibited tumor immune escape by inducing PD-L1 autophagic degradation. Cancer Sci. 2023; 114(7):2871-2881. PMC: 10323095. DOI: 10.1111/cas.15818. View

4.
Xu L, Che S, Chen H, Liu Q, Shi J, Jin J . PPARγ agonist inhibits c-Myc-mediated colorectal cancer tumor immune escape. J Cell Biochem. 2023; 124(8):1145-1154. DOI: 10.1002/jcb.30437. View

5.
Xu Y, Lin X, Xu J, Jing H, Qin Y, Li Y . SULT1E1 inhibits cell proliferation and invasion by activating PPARγ in breast cancer. J Cancer. 2018; 9(6):1078-1087. PMC: 5868175. DOI: 10.7150/jca.23596. View